כל המחקרים
גיוסPHASE1, PHASE2התערבותי

A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia

This research is looking into a new medicine called KK8123 for people aged 18 to 65 who have X-linked Hypophosphatemia (XLH). This is the very first time this medicine is being tested in humans. The main goal is to find out if KK8123 is safe, what the right dose might be, and how it behaves in the body. Researchers will also be checking if it helps improve the condition. The study involves different stages, including an initial health check, a period where participants receive the medicine, and an optional longer follow-up period. It's an important step in developing new treatments for XLH, aiming to understand the medicine better before it can be studied in larger groups.

במבט חטוף

סטטוס
גיוס
שלב
PHASE1, PHASE2
נותן חסות
Kyowa Kirin Co., Ltd.
יעד הרשמה
24
התחל
09 Oct 2024
השלמה משוערת
10 May 2028

על מה המחקר הזה?

This clinical trial is an important step in understanding a new medicine called KK8123, which is being developed for people with a condition called X-linked Hypophosphatemia (often shortened to XLH). XLH is a rare genetic disorder that affects how the body handles phosphate, a mineral vital for strong bones and teeth. People with XLH often have low levels of phosphate in their blood, which can lead to weakened bones, pain, and other health issues.

The study is called a 'first-in-human' study, which means it's the very first time this particular medicine is being given to people. Because of this, it's divided into two main parts (Phase 1 and Phase 2). In these early phases, the primary focus is not on whether the medicine cures XLH, but on making sure it's safe for people to take. Researchers will carefully check for any side effects and work out the best dose to give.

By taking part, individuals are helping doctors and scientists learn more about XLH and explore potential new treatments. The information gathered from this study will be crucial for deciding whether KK8123 can be tested in larger groups of people later on, with the hope that it might eventually become a new way to help manage XLH.

נקודות עיקריות

  • This is a 'first-in-human' study for a new XLH medicine, KK8123.
  • The primary goals are to check the medicine's safety, side effects, and how it acts in the body.
  • Participants must be adults (18-65) with XLH and good kidney function.
  • The study involves a screening period, a treatment period (32-44 weeks), and an optional extension.
  • Close medical monitoring will be provided throughout the study.
  • יש לך את הזכות לפרוש מהמחקר בכל עת.

מי עשוי להיות זכאי?

To be considered for this study, you need to be an adult between 18 and 65 years old. You must have a confirmed diagnosis of X-linked Hypophosphatemia (XLH) and blood tests showing low phosphate levels. Your kidney function also needs to be healthy enough to take part.

There are some other important requirements. You must weigh at least 6 stone 4 pounds (40 kg) and be able to give your informed consent. If you are female and could become pregnant, you'll need to have a negative pregnancy test and agree to use effective contraception during and for some time after the study. The same applies to male participants who could father a child. If you take pain medication, it needs to be at a stable dose. You also need to be willing to keep your diet and exercise routines consistent throughout the study.

האם מחקר זה יכול להתאים לך?

ענה על השאלות המהירות הללו כדי לבדוק אם אתה עשוי להיות זכאי. זהו מדריך בלבד — צוות המחקר מקבל את ההחלטה הסופית.

  1. האם אתה בין גיל 18 ל-65?
  2. Do you have a diagnosis of X-linked Hypophosphatemia (XLH)?
  3. Are your blood phosphate levels currently low?
  4. Do you weigh at least 6 stone 4 pounds (40 kg)?
  5. Are you able to use contraception if you could become pregnant or father a child?
  6. Are you willing to stick to your usual diet and exercise routines during the study?
ענה על כל שאלה כדי לראות את התוצאה שלך.

מה כרוך בהשתתפות?

If you decide to take part, the first step is a 'screening period' which can last up to 28 days. During this time, you'll have various checks and tests to make sure you meet all the requirements for the study. If you qualify, you'll enter the 'treatment period'. This part involves taking the study medicine, KK8123, and attending regular appointments so the research team can monitor your health, check for any side effects, and see how the medicine is working. This treatment and observation period will last between 32 and 44 weeks. After this, some participants might be offered the chance to continue in an 'extension period' for further monitoring if they wish. Throughout the study, you'll be giving blood samples and having other medical assessments.

סיכונים ותועלות פוטנציאליים

Taking part in any clinical trial involves potential benefits and risks. For this study, potential benefits aren't certain, as the main goal is to understand the medicine's safety and how it works, rather than directly treating your XLH. However, you will receive close medical monitoring. Potential risks include side effects from the new medicine, which are currently unknown as this is the first time it will be given to humans. There may also be discomfort from blood tests and other procedures. It's very important to remember that you can choose to leave the study at any time, for any reason, without it affecting your usual medical care.

מיקומים (9)

  • University of California - San Francisco
    מיקוד מאומת
    סן פרנסיסקו, ארצות הברית· גיוס
  • Yale Center for XLH/ Yale University School of Medicine
    מיקוד מאומת
    ניו הייבן, ארצות הברית· גיוס
  • Indiana University School of Medicine University Hospital
    מיקוד מאומת
    אינדיאנפוליס, ארצות הברית· גיוס
  • מאיו קליניק
    מיקוד מאומת
    רוצ'סטר, ארצות הברית· עדיין לא מגייסים
  • Vanderbilt University Medical Center
    מיקוד מאומת
    נאשוויל, ארצות הברית· גיוס
  • Hoptial Bictre
    מיקוד מאומת
    Le Kremlin-Bicêtre, France· גיוס
  • Institute of Osteology and Biomechanics (IOBM)
    מיקוד מאומת
    המבורג, גרמניה· גיוס
  • Universitaetsklinikum Wurzburg
    מיקוד מאומת
    וירצבורג, גרמניה· גיוס
  • Hospital Universitario La Paz
    מיקוד מאומת
    מדריד, ספרד· גיוס

שאלות נפוצות

What is X-linked Hypophosphatemia (XLH)?

XLH is a rare inherited condition that causes low levels of phosphate in the blood, leading to problems like soft bones, pain, and dental issues.

What is the purpose of KK8123?

KK8123 is a new medicine being developed to potentially help manage XLH. This study is the first time it's being tested in people to check its safety and how it works.

כמה זמן נמשך המחקר?

The initial screening period can be up to 28 days. If you qualify, the main treatment part of the study will last between 32 and 44 weeks, with an option to continue in an extension period.

Will I receive KK8123 if I join?

Yes, if you meet the study requirements and are enrolled, you will receive the study medicine, KK8123, as this is a dose-escalation study where participants receive the active drug.

What happens if I change my mind during the study?

You are free to leave the study at any time, for any reason. Your decision will not affect your ongoing medical care.

כיצד לגלות עוד

Kyowa Kirin

תמיד התייעץ עם רופא המשפחה או המומחה שלך לפני שתחליט להשתתף במחקר.

מעוניינים להשתתף?

רשום את התעניינותך

שתף את הפרטים שלך וצוות המחקר עבור "A First-in-human Study of KK8123 in Adults With X-linked Hyp…" ייצרו איתך קשר אם אתה עשוי להיות זכאי. תמיד התייעץ עם הרופא שלך לפני שאתה מסכים להשתתף.

דיון

דיון קהילתי

מופעל על ידי הפורום שלנו ב community.patient.info. אנא היו מכבדים — זה אינו ייעוץ רפואי.